GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vaxil Bio VXL.V · CAD

Health Care · TSX Venture · 🇨🇦 Canada

Compare

0.11

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in CAD, from our data supplier.

FY2025

Net income

C$522,000

FY2016FY2025

Free cash flow

−C$158,000

FY2016FY2025

Shareholders' equity

C$1.4m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit———−C$2,000−C$25,000−C$57,000−C$100,000−C$56,000−C$47,000−C$22,000
Research and development—C$12,000C$114C$343,000C$539,000C$619,000C$750,000C$575,000C$838,000C$585,000
Operating income−C$179,000−C$148,000−C$254−C$584,000−C$986,000−C$1.3m−C$1.1m−C$1.0m−C$1.8m−C$4.5m
Net incomeC$522,000−C$178,000−C$254−C$584,000−C$986,000−C$1.4m−C$1.2m−C$1.0m−C$1.8m−C$4.5m
Diluted earnings per share0.00-0.00-0.00-0.00-0.01-0.01-0.01-0.01-0.04-0.10

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsC$1.4mC$733,000C$976,000C$1.5mC$2.3mC$1.7mC$205,000C$890,000C$310,000C$1.2m
Cash and short-term investments——C$938,000C$1.5mC$2.2mC$1.5mC$83,000C$753,000C$169,000C$1.0m
Total liabilitiesC$5,000C$17,000C$85,000C$405,000C$585,000C$857,000C$788,000C$455,000C$797,000C$561,000
Debt—————C$9,000C$17,000C$5,000C$78,000C$17,000
Shareholders' equityC$1.4mC$716,000C$891,000C$1.1mC$1.7mC$804,000−C$583,000C$435,000−C$487,000C$656,000
Shares outstanding137m137m137m137m137m104m89m88m50m47m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−C$158,000−C$188,000−C$561,000−C$734,000−C$1.1m−C$1.1m−C$596,000−C$943,000−C$1.0m−C$1.5m
Capital spending—————————−C$164,000
Free cash flow−C$158,000−C$188,000−C$561,000−C$734,000−C$1.1m−C$1.1m−C$596,000−C$943,000−C$1.0m−C$1.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−C$70,000−C$109,000−C$44,000−C$32,000−C$37,000−C$74,000−C$33,000−C$44,000
Net income−C$64,000−C$107,000C$570,000−C$20,000C$36,000−C$70,000−C$22,000−C$49,000
Diluted earnings per share-0.00-0.000.00-0.000.00-0.00-0.00-0.00
Total assetsC$1.2mC$1.3mC$1.4mC$675,000C$697,000C$684,000C$733,000C$820,000
Shareholders' equityC$1.2mC$1.3mC$1.4mC$667,000C$691,000C$644,000C$716,000C$738,000

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-32.6%-33.2%-16.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings38.0-3.2-5527.7-1.9-4.3-1.9-0.1-0.1-0.1-0.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 50-to-1 reverse split · 15 May 2025
  • 2-to-1 reverse split · 10 Mar 2016
  • 7-to-1 reverse split · 9 Oct 2014
  • 2-to-1 reverse split · 30 Oct 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.